# 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer

> **NCT06250244** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** 177Lu-LNC1011

## Key facts

- **NCT ID:** NCT06250244
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06250244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06250244, "177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06250244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*